Followers | 43 |
Posts | 5751 |
Boards Moderated | 0 |
Alias Born | 04/12/2021 |
Sunday, December 19, 2021 10:24:01 PM
The Term Loan will mature on the fourth anniversary of the closing date and accrues interest at an annual rate equal to 11.25% plus the greater of (a) one-month LIBOR and (b) one percent per annum, and interest will be payable monthly in arrears in cash. The Term Loan does not require any amortization, and the entire unpaid balance will be payable upon maturity.
The funding of the Term Loan is subject to a number of conditions precedent including the repayment of at least 99.7% of the Notes and approval by the Company’s shareholders of the Term Loan, an increase in the authorized share capital of the Company and the issuance of the Warrants. The Company intends to convene a general meeting of the Company to consider these matters in January 2022.
In connection with the Term Loan, the Company has agreed, subject to drawdown of the Term Loan, to issue warrants (the “Warrants”) exercisable for 2,500,000 of the Company’s ADSs to Perceptive. The per ADS exercise price of the Warrants is equal to the lower of i) the 10-day volume weighted average price (“VWAP”) for the Company’s ADSs for the 10 business days prior to December 15, 2021 and ii) the 10-day VWAP for the Company’s ADSs for the 10 business days prior to the drawdown date of the funding under the Term Loan. The Warrants are exercisable, in whole or part, until the seventh anniversary of the date of drawdown of the funding under the Term Loan.
In addition to the Term Loan, the Company has entered into exchange agreements (the “Exchange Agreements”) with five institutional investors that hold approximately $99.7million of the outstanding Notes, which are puttable by the Holders in April 2022. Under the terms of this agreement each holder will receive $ 0.87 of cash and the equivalent of $0.08 of the Company’s ADS (based upon the 5-day volume weighted average price for the Company’s ADSs for the 5 business days prior to December 10, 2021, discounted by 13%) per $1 nominal value of the Notes. The consummation of the Exchange Agreements is conditional upon (among other things) the approval by the Company’s shareholders of the issuance of ADSs pursuant to the Exchange Agreements and certain matters related to the funding of the Term Loan, with such approvals to be included in the agenda of the January 2022 general meeting of the Company.
Two of the Company’s existing board members, Jim Walsh and Kevin Tansley, have announced their intention to retire from the Company’s board in the coming months. The Company intends to retain an internationally recognized executive search firm to identify three suitably experienced and qualified candidates to join the Company’s board as independent directors. Following these appointments, the Company’s board will consist of five independent non-executive directors and two executive directors, Mr. Ronan O’Caoimh, Chairman and Chief Executive Officer and Mr. John Gillard, Chief Financial Officer. As part of this process the Company will seek to increase the diversity of its board membership.”
https://www.otcmarkets.com/filing/html?id=15423788&guid=jdfwkePL-zw-B3h
my posts are always theory and not financial advice
Recent TRIB News
- Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development • GlobeNewswire Inc. • 05/08/2024 02:36:58 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/08/2024 04:15:26 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/07/2024 08:25:53 PM
- Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates • GlobeNewswire Inc. • 04/04/2024 11:30:02 AM
- Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 10:39:07 PM
- Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule • GlobeNewswire Inc. • 03/08/2024 03:03:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/15/2024 07:11:36 PM
- Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change • GlobeNewswire Inc. • 02/15/2024 05:34:50 PM
- Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change • GlobeNewswire Inc. • 02/13/2024 02:00:12 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 02/10/2024 12:51:28 AM
- Trinity Biotech to Present at Emerging Growth Conference • GlobeNewswire Inc. • 02/08/2024 01:30:00 PM
- Trinity Biotech Announces Application for Early Sjogrens Syndrome Test Panel PLA Code • GlobeNewswire Inc. • 02/07/2024 01:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/01/2024 04:37:17 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/01/2024 04:33:32 PM
- Trinity Biotech Announces Q3 2023 Financial Results & Business Update • GlobeNewswire Inc. • 01/31/2024 12:05:00 PM
- Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India • GlobeNewswire Inc. • 01/31/2024 12:02:00 PM
- Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies, Inc. • GlobeNewswire Inc. • 01/31/2024 12:00:00 PM
- Trinity Biotech plc to Host Investor Call • GlobeNewswire Inc. • 01/30/2024 10:23:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/02/2024 09:17:57 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/02/2024 09:13:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/02/2024 07:02:39 PM
- Trinity Biotech Announces It Has Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya • GlobeNewswire Inc. • 12/27/2023 01:57:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/19/2023 06:56:39 PM
- Trinity Biotech Announces Management Changes • GlobeNewswire Inc. • 12/18/2023 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/29/2023 02:00:03 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM